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Aims Both cyclooxygenase-2 (COX-2) and the transcription factor signal transducer and activator of
transcription 3 (Stat3) are involved in adaptive growth and survival of cardiomyocytes. In ventricular
cardiomyocytes, prostaglandin E2 (PGE2), a major COX-2 product, leads to adaptive growth via Stat3
activation, but whether this transcription factor acts as a signalling molecule in PGE2-induced cell
survival is unknown. Therefore, the purpose of this study was to determine whether PGE2 counteracts
cardiac apoptosis induced by doxorubicin (DOX), and if so, whether Stat3 plays a critical role in this
cardioprotective effect.
Methods and results Neonatal rat ventricular cardiomyocytes were incubated with DOX (0.5 mM) and/or
PGE2 (1 mM). Apoptosis was assessed by determining caspase3 activation and apoptotic DNA fragmenta-
tion. The role of Stat3 was evaluated in vitro and in vivo by transfecting cardiomyocytes with siRNA
targeting rat Stat3 and by using cardiomyocyte-restricted Stat3 knockout (Stat3 KO) mice, respectively.
Incubation of ventricular cardiomyocytes with PGE2 led to a time-dependent decrease in the
DOX-induced caspase3 activation, reaching a maximal inhibition of 70+5% after 4 h. Similarly, PGE2
inhibited DOX-induced DNA fragmentation by 58+5% after 24 h. This antiapoptotic action of PGE2
was strongly reduced by the ERK1/2 inhibitor, U0126, whereas the p38 MAP kinase inhibitor,
SB203580, had no effect. Depleting Stat3 expression by 50–60% in isolated ventricular cardiomyocytes
markedly reduced the protective effect of PGE2 on DOX-induced caspase3 activation and DNA fragmen-
tation. Likewise, the stable PGE2 analogue, 16,16-dimethyl-PGE2, was unable to counteract cardiac
apoptosis induced by DOX in Stat3 KO mice.
Conclusion Our results demonstrate that PGE2 prevents myocardial apoptosis induced by DOX. This






The anthracycline doxorubicin (DOX) is one of the most effec-
tive anticancer drugs and frequently used to treat solid
tumours and haematological malignances. Unfortunately, its
use is limited by cumulative dose-related cardiotoxicity.1,2
The pathogenesis of DOX has not yet been clearly identiﬁed.
The presence of a large amount of apoptotic cells in the
myocardium of DOX-treated patients could contribute to
the dilated cardiomyopathy and heart failure induced by
this anthracycline.3,4 Among the mechanisms involved in
DOX-induced cardiotoxicity, there is formation of reactive
oxygen radicals,5,6 leading to apoptosis in cardiomyocytes.7,8
Multiple studies indicate that cyclooxygenase-2 (COX-2)
and its downstream products such as prostaglandin E2
(PGE2) and prostacyclin (PGI2) play a cardioprotective
role, in particular counteracting DOX treatment9–11 and
ischaemia/reperfusion (I/R) injury12–15 whose deleterious
effects are mediated in a similar manner as DOX-induced
injury, including the generation of reactive oxygen species.16
Indeed, COX-2 inhibition aggravates DOX-mediated cardio-
myocyte injury including apoptosis in vitro and in vivo.9–11
Consistently, the prostacyclin analogue, iloprost, was
found to reduce cardiac cell apoptosis and to ameliorate
the cardiac function in DOX-treated mice,11 but the mech-
anisms of protection are still unclear.
There is increasing evidence that the signal transducer and
activator of transcription 3 (Stat3) plays a cardioprotective
role in the heart.17–21 Indeed, conditional knockout (KO)
mice harbouring a cardiomyocyte-restricted deletion of Stat3
KO (Stat3 KO) showed increased susceptibility to cardiac
injury caused by myocardial ischaemia, inﬂammation, or
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drug toxicity.18,22 Stat3 has also been suggested as a critical
intermediate to provide cardioprotection from DOX.22–23
At the present time, there is little information concerning
the effect of PGE2 on Stat3. In ventricular cardiomyocytes,
we have recently demonstrated that PGE2 leads to an
increase in cell size and protein synthesis via a Stat3-
dependent pathway involving ERK1/2.24 However, whether
Stat3 acts as a signalling molecule in PGE2-induced cell
survival is unknown. Therefore we determined whether
PGE2 counteracts the apoptotic effect of DOX in neonatal
rat ventricular cardiomyocytes and whether Stat3 and/or
ERK1/2 are involved. To further evaluate the interaction
between PGE2 and Stat3, we also investigated the role of
Stat3 in the antiapoptotic effect of PGE2 in vivo using
Stat3 KO and wild-type (WT) mice.
2. Methods
2.1 Cell culture
This investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by US National Institues of Health
(NIH Publication No. 85–23, revised 1966). Neonatal ventricular
cardiomyocytes were isolated from 1–2-day-old Wistar rat ventri-
cles by digestion with trypsin-EDTA and type 2 collagenase as we
have previously described.24 For all experiments described herein,
cells were used the third or fourth day of culture, after 16–24 h in
DMEM medium depleted in FCS.
2.2 Small interfering RNA transfection
Stat3 was silenced by using a siRNA targeting rat Stat3 (Stat3-siRNA)
with a mix of the following sequences: 50-GGCUGAUCAUUUAUAU
AAA-30 and 50- GAGGGUCUCGGAAAUUUAA-30. These siRNAs which
were provided by Qiagen AG (Hombrechtikon, Switzerland), were
annealed according to manufacturer’s instructions and stored
at 2208C. Cardiomyocytes were transfected using lipofectamine
2000 (Invitrogen) reagent, following the manufacter’s protocol.
Brieﬂy, 24 h after cardiomyocytes were plated, transfection was
proceeded with a mix containing lipofectamine 2000 reagent and
Stat3-siRNA (300 pmol) in OptiMEMþGlutaMAX medium (Invitrogen).
Cardiomyocytes were stimulated, with the different drugs 24–36 h
after transfection. For control, cells were transfected as described
for siRNA experiments with non-silencing siRNA (300 pmol) (50-UUCU
CCGAACGUGUCACGU-30) which is ineffective in rat cells since it has
no mammalian target.
2.3 In vivo experiments
WT or Stat3 cardiomyocytes restricted KO (Stat3 KO) mice (13–16
weeks old and weighting 20–40 g) were used in this study. Genotype
was conﬁrmed by DNA extraction and PCR analysis as previously
described.25 DOX was administered as a single intraperitoneal
(i.p.) injection at a dose of 12 mg/kg. The stable PGE2 analogue,
16,16-dimethyl-PGE2 (dmPGE2) was administered (i.p.) at a dose
of 10 mg/kg trice daily from 2 days before DOX and continued
until 5 days after DOX. The mice were divided into eight groups:
(i) WT as control, (ii) Stat3 KO as control, (iii) WTþdmPGE2, (iv)
Stat3 KOþdmPGE2, (v) WTþDOX, (vi) Stat3 KOþDOX, (vii) WTþ
dmPGE2þDOX, (viii) Stat3 KOþdmPGE2þDOX. When the animals
were sacriﬁced, the hearts were removed and cardiac tissue
processed for determination of apoptotic DNA fragmentation. The
doses of dmPGE2 and DOX were based on previous work.
11,26
2.4 Western blotting
Cardiomyocytes were starved of serum overnight and subjected to
treatment as indicated in the ﬁgure legends. After stimulation in
serum-free DMEM, cells were washed, lysed, and analysed by
western blotting as previously described.24 Brieﬂy, total cell
proteins were separated by SDS–PAGE and blotted onto nitrocellu-
lose membrane. Afterwards, membranes were probed against
cleaved caspase3 (17 kDa fragment) or phosphorylated Stat3 (Cell
Signaling Technology, Denvers, MA, USA), and reprobed against
glyceraldehyde-3-phosphate dehydrogenase (Chemicon Inter-
national Inc., Hampshire, UK) or Stat3 total (Upstate Biotechnology,
Lake Placid, NY, USA).
2.5 DNA fragmentation
DNA fragmentation was quantiﬁed by measuring the content of
intracellular nucleosomes. Neonatal rat ventricular cardiomyocytes
were cultured in 6-well plates for 2 days (106 cells per well). There-
after, cardiomyocytes were starved of serum for 24 h and subjected
to treatment as indicated in the ﬁgure legends. After stimulation in
serum-free DMEM, cells were washed with ice-cold PBS (phosphate-
buffered saline) and lysed with 60 ml of the same buffer used for
western blotting.24 Concerning the in vivo studies, minced cardiac
tissue was homogenized in the same lysis buffer. The cellular and
tissue lysates were used for protein determination and for quanti-
tative evaluation of histone-associated DNA fragments by photo-
metric enzyme immunoassay (Cell Death Detection ELISAPLUS,
Roche Diagnostics, Germany) according to the manufacturer’s
instructions. Results are reported as arbitrary absorbance units
normalized to milligram of proteins.
2.6 Determination of cardiomyocyte viability
Cell viability was evaluated by colorimetric MTT assay (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) which
is based on the reduction of MTT into a blue formazan dye by
functional mitochondria of viable cells. Brieﬂy, at the end of
treatments, cardiomyocytes were washed twice with PBS prior to
incubation with 5 mg/mL MTT for 3 h at 378C in an atmosphere
of 5% CO2. Thereafter, cells were again washed twice with PBS
before lysing cell membranes with dimethyl sulfoxane. The amount
of MTT formazan was quantiﬁed by determining the absorbance
at 540 and 570 nm. Cell viability was also evaluated by staining
cardiomyocytes with trypan blue (0.04% in PBS).
2.7 Chemicals
PGE2 and dmPGE2 were purchased from Sigma-Aldrich GmbH (Buchs,
Switzerland), dmPGE2 was prepared as previously described.
27 MTT,
SB203580, AG490, and piceatannol were obtained from Calbiochem
(Dietikon, Switzerland), while U0126 was from Biomol Research
Laboratories (Plymouth Meeting, PA, USA).
2.8 Statistical analysis
All values are expressed as mean+ SEM with n referring to the
number of experiments. Linear regression analysis was made using
the Origin software (Microcal Software, Inc., Northhampton, MA,
USA). Differences between groups were determined using either
two-tailed unpaired Student’s t-tests or ANOVA, followed by
Bonferroni’s post hoc test where applicable. P , 0.05 was accepted
as statistically signiﬁcant.
3. Results
3.1 Effect of prostaglandin E2 on
doxorubicin-induced myocardial apoptosis
and decrease of cell viability
To investigate whether PGE2 can counteract DOX-induced
apoptosis in ventricular cardiomyocytes, we incubated
cells with or without PGE2 (1 mM) for 30 min before adding
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DOX (0.5 mM) for 4–24 h (Figure 1). Thereafter, we analysed
activation of caspase3 by measuring the expression of the
17 kDa fragment of cleaved caspase3. As is illustrated in
Figure 1A, PGE2 caused a signiﬁcant decrease in the acti-
vation of caspase3 induced by DOX after 4 h (70+5%), 8 h
(57+6%), 16 h (57+11%), or 24 h (44+3%). DOX also
increased apoptotic DNA fragmentation by 109+20 and
319+54% after 16 and 24 h of treatment, respectively,
but had no signiﬁcant effect after 4 and 8 h (Figure 1B).
The presence of PGE2 abolished the DNA fragmentation
induced after 16 h of incubation with DOX and inhibited
that after 24 h of treatment by 49+7%.
Cell viability was determined by using the MTT assay.
Figure 2A illustrates that DOX decreased cell viability in a
time- and concentration-dependent manner. As for apoptotic
DNA fragmentation, PGE2 (1 mM) abolished the decrease in
cell viability observed after 16 h of incubation with DOX
(0.5 mM), and markedly inhibited that after 24 h of treatment
with DOX (Figure 2B). Similar results were obtained with the
trypan blue exclusion method (data not shown).
To compare DOX-induced DNA fragmentation with cell
viability, linear regression analysis was used to ﬁt the data
described in Figures 1B and 2B (see Figure 2C). This analysis
shows a high linear correlation between apoptotic DNA frag-
mentation and cell viability in cardiomyocytes treated or
not with DOX (0.5 mM) for 4, 16, and 24 h in the presence
and absence of PGE2 (1 mM).
Our results indicate that in ventricular cardiomyocytes,
PGE2 counteracts DOX-induced apoptosis and the associated
decrease in cell viability.
Figure 1 Prostaglandin E2 inhibits doxorubicin-induced caspase3 activation and apoptotic DNA fragmentation in ventricular cardiomyocytes. Cells were pre-
treated or not (control, C) with prostaglandin E2 (P, 1 mM) for 30 min prior to incubation with doxorubicin (D, 0.5 mM) during different time periods (4, 8, 16,
and 24 h). (A) After these incubation periods, caspase3 activation was analysed in cellular extracts by determining the level of the catalytically active
17 kDa fragment by western blotting. Representative blots are shown at the top. Equal gel loading was assessed using an anti-GAPDH antibody. Speciﬁc bands
corresponding to activated caspase3 were quantiﬁed by densitometry and expressed as percentage of doxorubicin-induced formation of the 17 kDa fragment.
(B) After the incubation periods with doxorubicin, DNA fragmentation was analysed by measuring histone-associated DNA fragments. Results were calculated
as arbitrary absorbance units normalized to mg of proteins and are expressed as percentage of control. *P , 0.05 compared with values from doxorubicin-treated
cells, †P , 0.05 compared with control values (n ¼ 4). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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3.2 Critical role of ERK1/2 in the antiapoptotic
effect of prostaglandin E2
We have previously reported that in ventricular cardiomyo-
cytes, ERK1/2 is critical for PGE2-induced Stat3 activation
as assessed by nuclear tyrosine phosphorylation and DNA-
binding activity. Both ERK1/2 and Stat3 have been shown to
play an essential role in PGE2-stimulated cell growth.
24 In
this study, we investigated the role of ERK1/2 and p38
MAPK in the antiapoptotic responses induced by PGE2 in
cardiomyocytes exposed to DOX (0.5 mM) for 4 or 24 h. To
this purpose we used the speciﬁc inhibitors of the ERK1/2
and p38 MAPK signalling pathways, U0126 and SB203580,
respectively.28 U0126 suppresses the activation of MEK1/2
leading to the inhibition of its downstream target ERK1/2.28
SB203580 speciﬁcally inhibits a and b p38 MAP kinases, the
main isoforms expressed in cardiomyocytes,28,29 but it has
Figure 2 Effect of doxorubicin and prostaglandin E2 on myocardial cell viability. (A) Cardiomyocytes were treated or not with the indicated concentration of
doxorubicin (0.05–5 mM) for 4, 16, and 24 h, respectively. Thereafter, cell viability was determined by using the MTT assay. Each line represents mean+ SEM of
three separate experiments (n ¼ 3 wells in each experiment). Results are expressed as percentage of the corresponding control. (B) Cells were pretreated or not
with prostaglandin E2 (1 mM) for 30 min prior to incubation with doxorubicin (0.5 mM) during different time periods (4, 16, and 24 h). After these incubation
periods, cell viability was determined by using the MTT assay. Results are expressed as percentage of the control. *P , 0.05 compared with control values
(n ¼ 3–4). (C) The apoptotic DNA fragmentation observed after 4, 16, or 24 h of incubation with 0.5 mM doxorubicin in the presence or absence of 1 mM PGE2
(see Figure 1) was compared with that of cell viability shown in (A) by using linear regression analysis to ﬁt the data. R, correlation factor, SD, standard deviation.
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no effect on g and d p38 MAP kinases.30 As shown in Figure 3A,
U0126, but not SB203580, abolished the PGE2-induced Stat3
activation which was observed after 90 min of stimulation
by determination of cellular Stat3 tyrosine phosphorylation.
To evaluate the role of ERK1/2 and p38 MAPK pathways
on DOX-induced apoptosis in the presence and absence of
PGE2, cells were incubated for 30 min with U0126 (10 mM)
or SB203580 (10 mM). Thereafter, cardiomyocytes were
stimulated for 30 min with PGE2 (1 mM) before DOX (0.5 mM)
was added. Activation of caspase3 was determined after 4 h
of DOX treatment, while generation of DNA fragmentation
was assessed after 24 h of incubation with DOX. As shown in
Figure 3B, U0126 strongly reduced the antiapoptotic effect
of PGE2 on DOX-induced caspase3 activation, whereas
SB203580 had not signiﬁcant effect. Similarly, the presence
of U0126, but not SB203580, abolished the protective effect
Figure 3 ERK1/2 plays a role in the inhibitory effect of prostaglandin E2 on doxorubicin-induced activation of caspase3 and DNA fragmentation. Cardiomyocytes
were incubated for 30 min with U0126 (10 mM) or SB203580 (SB, 10 mM), prior to stimulation with prostaglandin E2 (1 mM). (A) After 90 min of prostaglandin E2
stimulation, Stat3 tyrosine phosphorylation (Stat3-P) was analysed in cellular extracts by western blotting. A representative blot is shown: similar results were
obtained in four separate experiments. (B) After 30 min of prostaglandin E2 stimulation, cells were incubated with doxorubicin (0.5 mM) during 4 h. At the end of
this incubation period, caspase3 activation was analysed in cellular extracts by determining the level of the catalytically active 17 kDa fragment by western
blotting. A representative blot is shown at the top of (B) (C, control, P, prostaglandin E2, D, doxorubicin). Equal gel loading was assessed using an anti-GAPDH
antibody. Speciﬁc bands corresponding to activated caspase3 were quantiﬁed by densitometry and expressed as percentage of doxorubicin-induced formation of
the 17 kDa fragment. (C) After 30 min of prostaglandin E2 stimulation, cells were incubated with doxorubicin (0.5 mM) during 24 h. At the end of this incubation
period, DNA fragmentation was analysed by measuring histone-associated DNA fragments. Results were calculated as arbitrary absorbance units normalized to mg
of proteins and are expressed as percentage of doxorubicin-induced DNA fragments. *P , 0.05 compared with values from doxorubicin-treated cells (n ¼ 4).
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of PGE2 on DOX-induced DNA fragmentation (Figure 3C). It
appears that ERK1/2 but not p38 MAPK is involved in the
protective inﬂuence of PGE2 counteracting apoptosis in
cardiomyocytes exposed to DOX.
3.3 Critical role of signal transducer and activator
of transcription 3 in the antiapoptotic effect of
prostaglandin E2 in vitro
To evaluate the role of Stat3 in the antiapoptotic effect of
PGE2 in vitro, we transfected cardiomyocytes with siRNA
targeting rat Stat3. This treatment decreased Stat3
expression by 50–60%, 40 h after transfection of cardiomyo-
cytes when compared with cells transfected with non-
silencing RNA (control siRNA) (Figure 4, top). This Stat3
knock-down effect remained sustained until 48 h after
transfection with anti-Stat3 siRNA (data not shown). After
incubation with DOX, caspase3 activation, normalized to
Stat3 expression, was increased in both control and
anti-Stat3 siRNA transfected cells (Figure 4). PGE2 signiﬁ-
cantly decreased DOX-induced caspase3 activation in the
control siRNA transfected cardiomyocytes, whereas it had
no effect in the anti-Stat3 siRNA transfected cells. Exposure
of cardiomyocytes to DOX for 24 h also increased apoptotic
fragmentation of DNA in both control and anti-Stat3 siRNA
transfected cells (Figure 5A). As for caspase3 activation,
PGE2 decreased DOX-induced DNA fragmentation in the
control siRNA transfected cells. In contrast, this antiapoptotic
effect of PGE2 was virtually abolished in the anti-Stat3 siRNA
transfected cardiomyocytes. Since the transfection technique
appears to increase basal DNA fragmentation (compare
Figure 1), resulting in apparently smaller effects of DOX
and PGE2, we also investigated the role of Stat3 in the
antiapoptotic effect of PGE2 on DOX-induced DNA frag-
mentation by using the Stat3 pathway inhibitors AG49031
Figure 4 Small interfering RNA targeting Stat3 blocks the inhibitory effect
of prostaglandin E2 on doxorubicin-induced activation of caspase3. Thirty-six
hour after transfection of cardiomyocytes with control small interfering RNA
or small interfering RNA targeting Stat3 (Stat3 siRNA), cells were pretreated
or not (ctrl) with prostaglandin E2 (1 mM) for 30 min prior to incubation with
doxorubicin (0.5 mM) during 4 h. Thereafter, the expression of Stat3 as well as
that of the active caspase3 fragment of 17 kDa was analysed in cellular
extracts by western blots. Representative blots are shown at the top. Speciﬁc
bands corresponding to activated caspase3 were quantiﬁed by densitometry
and normalized to Stat3 expression. Equal gel loading was assessed using an
anti-GAPDH antibody. Results are expressed as percentage of
doxorubicin-induced formation of the 17 kDa fragment. *P , 0.05 compared
with values from doxorubicin-treated cells (n ¼ 5).
Figure 5 Small interfering RNA targeting Stat3 and pharmacological inhi-
bition of Stat3 reduce the inhibitory effect of prostaglandin E2 on
doxorubicin-induced apoptotic DNA fragmentation. (A) 24 h after transfection
of cardiomyocytes with control siRNA or siRNA targeting Stat3 (Stat3 siRNA),
cells were pretreated or not (control, ctrl) with prostaglandin E2 (1 mM) for
30 min prior to the incubation with doxorubicin (0.5 mM) during 24 h. There-
after, DNA fragmentation was analysed. (B and C) Cells were incubated for 1 h
with the Stat3 inhibitors piceatannol (10 mM) or AG490 (10 mM) prior to stimu-
lation with prostaglandin E2 (1 mM). (B) After 90 min of prostaglandin E2
stimulation, Stat3 tyrosine phosphorylation (Stat3-P) was analysed in cellular
extracts by western blotting. A representative blot is shown: similar results
were obtained in three separate experiments. (C) After 30 min of prostaglan-
din E2 stimulation, cells were incubated with doxorubicin (0.5 mM) during
24 h. At the end of this incubation period, DNA fragmentation was analysed.
*P , 0.05 compared with values from doxorubicin-treated cells; †*P , 0.05
compared with values from control cells (n ¼ 4).
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and piceatannol.32 Both these inhibitors strongly inhibited
PGE2-induced Stat3 phosphorylation (Figure 5B) as well as
the antiapoptotic effect of PGE2 on the DNA fragmentation
induced by DOX (Figure 5C).
3.4 Critical role of signal transducer and activator
of transcription 3 in the antiapoptotic effect of
prostaglandin E2 in vivo
In order to evaluate the role of Stat3 in the antiapoptotic
effect of PGE2 in vivo, we used Stat3 KO mice
25 and their
littermate controls (WT). Stat3 KO and WT mice were each
divided in four groups: control, þdmPGE2, þDOX, and þ
dmPGE2þDOX. The survival rate of animals was 90–100% in
all groups. DOX treatment did not impair survival rate,
neither in WT animals nor Stat3 KO mice. Likewise, the
heart weight/body weight ratio was similar in all animal
groups. After treatment, cardiac tissue (n ¼ 5–7 animals
per group) was assessed for apoptosis by measuring DNA
fragmentation. As shown in Figure 6, no difference was
observed in myocardial DNA fragmentation between WT
and Stat3 KO mice at baseline. Treatment with DOX
induced an increase in cardiac DNA fragmentation which
reached a higher signiﬁcance level in Stat3 KO mice than
in WT animals. Our results conﬁrm previous data from the
literature reporting that Stat3 KO mice are more sensitive
to DOX treatment than WT animals.22 As expected, the
increase in DOX-induced cardiac apoptosis was markedly
attenuated by dmPGE2 injections in WT mice. In contrast,
the same treatment remained without effect in Stat3
KO mice. Of note, in dmPGE2-treated animals, cardiac apop-
tosis was signiﬁcantly different between WT and Stat3 KO
mice, whether or not animals had been injected with DOX.
Our investigations, both in vitro and in vivo, demonstrate
that the protective effect of PGE2 against DOX-induced
cardiac apoptosis is Stat3-dependent.
4. Discussion
Our study revealed that in ventricular cardiomyocytes, PGE2
exerts antiapoptotic activities which are mediated by Stat3
involving ERK1/2. Indeed, PGE2 was found to counteract
DOX-induced caspase3 activation and apoptotic DNA frag-
mentation which was associated with impaired survival in
ventricular cardiomyocytes. By transfecting cardiomyocytes
with siRNA targeting speciﬁcally rat Stat3, we obtained 50–
60% inhibition of Stat3 expression. In these Stat3 silenced
cells, the antiapoptotic effect of PGE2 on DOX-induced
caspase3 activation and DNA fragmentation was signiﬁcantly
reduced. Likewise, the Stat3 pathway inhibitors, piceatan-
nol and AG490, abolished the antiapoptotic effect of PGE2
on DNA fragmentation generated by DOX. The role of Stat3
in PGE2-induced antiapoptotic activity was further con-
ﬁrmed in vivo using WT and Stat3 KO mice. While treatment
with the stable analogue dmPGE2 signiﬁcantly inhibited the
DOX-induced increase in myocardial apoptotic DNA fragmen-
tation in WT mice, it had no effect in Stat3 KO mice.
According to a recently published, fundamental hypoth-
esis,33 the myocardium adaptation to stress depends on
the nature of the signalling stimulus. The cardiomyocyte
can either survive leading to beneﬁcial or adaptive hypertro-
phy34 or undergo apoptosis, which induces left ventricular
failure and dilation (maladaptive hypertrophy).35 Including
observations from a previous study,24 our results suggest
that PGE2 is beneﬁcial for the heart, favouring an adaptive
pattern of hypertrophy by its dual action on cell survival
and hypertrophic growth, via the activation of Stat3.
COX-2 has been shown to mediate PGE2 production in both
neonatal and adult cardiac myocytes.36,37 Moreover, several
in vitro and in vivo studies reported that COX-2 and its pros-
tanoid products as well as Stat3 similarly counteract DOX- and
oxidative stress-induced myocardial damage in both neonatal
and young adult ventricular cardiomyocytes.9–11,19,21–23
However, there is little information concerning the effect of
PGE2 or other COX-2-derived products on myocardial Stat3
activation and its cardioprotective role. Very recently, Qian
et al.38 using cardiac EP4-deﬁcient mice, reported that this
prostaglandin receptor plays a role in hypertrophy via acti-
vation of Stat3 which seems cardioprotective in mice with
myocardial infarction.
There is growing evidence that Stat3 plays an important
role in cardiac remodelling, particularly by promoting
cardiomyocyte survival and hypertrophy.19,20,23 Moreover,
it has been demonstrated that Stat3 activation confers
cardioprotection at the time of reperfusion in response to
ischaemic preconditioning and TNFa.15,17,25 Interestingly, a
recent study reported a decrease in myocardial Stat3
levels in the aged mouse heart associated with a loss of
cardioprotection induced by ischaemic post-conditioning.39
Consistent with our results, the prostacyclin analogue
iloprost was shown to prevent the release of lactate dehy-
drogenase induced by DOX in ventricular cardiomyocytes,
while COX-2 inhibition increased this deleterious response.9
In vivo, it has been shown that inhibition of COX-2 aggra-
vates DOX-induced cardiac injury as detected by cardiomyo-
cyte apoptosis and the release of lactate dehydrogenase
and cardiac troponin C.10 Moreover, Neilan et al.11 observed
that DOX-induced cardiac apoptosis and dysfunction was
signiﬁcantly higher in COX-2 KO than in WT mice, and
that this DOX-induced myocardial toxicity was attenuated
Figure 6 Stat3 plays a role in the inhibitory effect of 16,16-dimethyl pros-
taglandin E2 on doxorubicin-induced myocardial DNA fragmentation in vivo.
Wild-type and Stat3 knockout mice were treated or not (control) with the
stable prostaglandin E2 analogue 16,16-dimethyl prostaglandin E2 (PGE2)
for 2 days before and 5 days after a single injection of doxorubicin (DOX)
(12 mg/kg, i.p.). Thereafter, mice were killed, hearts were removed and
cardiac tissue processed for DNA fragmentation analysis. Apoptotic DNA frag-
mentation in cardiac tissue was assessed by measuring histone-associated
DNA fragments. Results are expressed as arbitrary absorbance units normal-
ized to mg of proteins. *P , 0.05 compared with values from doxorubicin-
treated mice (n ¼ 5–7 animals per group).
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by the stable prostacyclin analogue iloprost which was
administered 2 days before and 5 days after DOX injection.
The latter ﬁnding is in agreement with the myocardial
antiapoptotic effect of dmPGE2 we observed in vivo, using
a similar experimental protocol.
Interestingly, Delgado et al.40 showed in a murine model,
that when COX-2 inhibition treatment was initiated after
heart failure had been established by prolonged DOX admin-
istration, it attenuated further progression of this cardio-
myopathy. The authors reasoned that in their experimental
setting, the effects of COX-2 inhibition cannot be related
to an interaction with the effects of DOX. They further
speculate that the role of COX-2 is initially adaptive, attenu-
ating the deleterious effects during DOX treatment but
later, after removal of this stress, it becomes maladaptive,
leading to the progression of heart failure.
Conﬁrming the cardioprotective role of COX-2, several
studies have demonstrated that this enzyme and its products
reduce I/R injury12–15 and mediate the late phase of precon-
ditioning.15,41 Indeed, both prostaglandin receptor EP3 and
EP4 signalling have been reported to protect the heart
from I/R injury.13,14 Moreover, Xuan et al.15 have shown
that activation of Stat3 leading to up-regulation of COX-2
underlies the protective effect of late preconditioning
against myocardial I/R injury. From the point of view of a
positive feed back phenomenon, the stimulatory role of
PGE2 in Stat3 activation which we demonstrated in our
work, could contribute to this cardioprotective process in
cardiac myocytes.
In this study, we also found a role for ERK1/2 in the Stat3-
dependent, cardioprotective effect of PGE2, counteracting
DOX-induced apoptosis in cardiomyocytes. Indeed, inhibition
of the ERK1/2, but not of the p38 MAPK pathway, strongly
reduced the antiapoptotic effect of PGE2 on DOX-induced
caspase3 activation and DNA fragmentation in ventricular
cardiomyocytes. These observations are in agreement with
our previous results showing that in ventricular cardiomyo-
cytes, PGE2-induced Stat3 activation and hypertrophic
growth involves ERK1/2 but not p38 MAPK.24 Consistent
with our present results, it has been shown that ERK1/2 is
implicated in myocardial survival signalling, while p38 MAPK
appears to have pro- or antiapoptotic effects depending on
the experimental model.35 In neonatal ventricular cardio-
myocytes, ERK1/2 was found to prevent apoptosis in cells
exposed to the anthracycline daunomycin, whereas p38
MAPK appeared to be involved in the induction of apoptosis.42
Taken together, our data demonstrate that PGE2 prevents
ventricular cardiomyocytes from apoptosis induced by DOX,
and that Stat3 activation involving ERK1/2 plays a key role
in this protective effect. Our in vivo studies conﬁrm the
importance of Stat3 in the protective role of PGE2 against
DOX-induced cardiac apoptosis. Thus, our investigations
underline the potential signiﬁcance of the PGE2–Stat3 inter-
action for the development of novel therapeutic strategies
offering increased cardioprotection.
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